JOURNAL DESCRIPTION
The Medical Radiology and Radiation Safety journal ISSN 1024-6177 was founded in January 1956 (before December 30, 1993 it was entitled Medical Radiology, ISSN 0025-8334). In 2018, the journal received Online ISSN: 2618-9615 and was registered as an electronic online publication in Roskomnadzor on March 29, 2018. It publishes original research articles which cover questions of radiobiology, radiation medicine, radiation safety, radiation therapy, nuclear medicine and scientific reviews. In general the journal has more than 30 headings and it is of interest for specialists working in thefields of medicine¸ radiation biology, epidemiology, medical physics and technology. Since July 01, 2008 the journal has been published by State Research Center - Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency. The founder from 1956 to the present time is the Ministry of Health of the Russian Federation, and from 2008 to the present time is the Federal Medical Biological Agency.
Members of the editorial board are scientists specializing in the field of radiation biology and medicine, radiation protection, radiation epidemiology, radiation oncology, radiation diagnostics and therapy, nuclear medicine and medical physics. The editorial board consists of academicians (members of the Russian Academy of Science (RAS)), the full member of Academy of Medical Sciences of the Republic of Armenia, corresponding members of the RAS, Doctors of Medicine, professor, candidates and doctors of biological, physical mathematics and engineering sciences. The editorial board is constantly replenished by experts who work in the CIS and foreign countries.
Six issues of the journal are published per year, the volume is 13.5 conventional printed sheets, 88 printer’s sheets, 1.000 copies. The journal has an identical full-text electronic version, which, simultaneously with the printed version and color drawings, is posted on the sites of the Scientific Electronic Library (SEL) and the journal's website. The journal is distributed through the Rospechat Agency under the contract № 7407 of June 16, 2006, through individual buyers and commercial structures. The publication of articles is free.
The journal is included in the List of Russian Reviewed Scientific Journals of the Higher Attestation Commission. Since 2008 the journal has been available on the Internet and indexed in the RISC database which is placed on Web of Science. Since February 2nd, 2018, the journal "Medical Radiology and Radiation Safety" has been indexed in the SCOPUS abstract and citation database.
Brief electronic versions of the Journal have been publicly available since 2005 on the website of the Medical Radiology and Radiation Safety Journal: http://www.medradiol.ru. Since 2011, all issues of the journal as a whole are publicly available, and since 2016 - full-text versions of scientific articles. Since 2005, subscribers can purchase full versions of other articles of any issue only through the National Electronic Library. The editor of the Medical Radiology and Radiation Safety Journal in accordance with the National Electronic Library agreement has been providing the Library with all its production since 2005 until now.
The main working language of the journal is Russian, an additional language is English, which is used to write titles of articles, information about authors, annotations, key words, a list of literature.
Since 2017 the journal Medical Radiology and Radiation Safety has switched to digital identification of publications, assigning to each article the identifier of the digital object (DOI), which greatly accelerated the search for the location of the article on the Internet. In future it is planned to publish the English-language version of the journal Medical Radiology and Radiation Safety for its development. In order to obtain information about the publication activity of the journal in March 2015, a counter of readers' references to the materials posted on the site from 2005 to the present which is placed on the journal's website. During 2015 - 2016 years on average there were no more than 100-170 handlings per day. Publication of a number of articles, as well as electronic versions of profile monographs and collections in the public domain, dramatically increased the number of handlings to the journal's website to 500 - 800 per day, and the total number of visits to the site at the end of 2017 was more than 230.000.
The two-year impact factor of RISC, according to data for 2017, was 0.439, taking into account citation from all sources - 0.570, and the five-year impact factor of RISC - 0.352.
Medical Radiology and Radiation Safety. 2026. Vol. 71. № 1
DOI:10.33266/1024-6177-2026-71-1-106-112
T.Yu. Mushkarina1, E.G. Kuzmina1, L.Yu. Grivtsova1, G.V. Afonin1, V.A. Biryukov1,
S.A. Ivanov1, 2, A.D. Kaprin2, 3, 4
Response of Circulating Regulatory T Cells to Chemoradiotherapy
of Lung Cancer and Brachytherapy for Prostate Cancer
1 А.F. Tsyb Medical Radiological Research Centre, Obninsk, Russia
2 Peoples Friendship University of Russia (RUDN University), Moscow, Russia
3 National Medical Research Radiological Centre, Obninsk, Russia
4 Р.A. Hertsen Moscow Oncology Research Institute, Moscow, Russia
Contact person: Т.Yu. Mushkarina, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
ABSTRACT
Purpose: To evaluate the dynamics of circulating regulatory T cells (Treg) and changes in their adenosine-dependent functional suppressor activity during chemoradiotherapy of lung cancer (LC) and brachytherapy for prostate cancer (PC).
Material and methods: The study included 19 patients with LC (38 cytometric peripheral blood tests at three control points of chemoradiotherapy) and 23 patients with PC (66 cytometric tests at four control points of brachytherapy). Two control groups were used in the analysis: the main group (40 practically healthy people, blood donors: 22 women and 18 men) to assess the initial level of Treg cells in LC; and an additional group (14 practically healthy people, blood donors) to study the functional activity of Treg cells in patients with LC and PC. The content of Treg cells in patients at the onset of PC was compared with a subgroup of men in the main control group (n=18). Statistical data processing was performed using the Mann–Whitney U-test (pairwise comparison) and the Kruskal‒Wallis criterion (multiple comparison).
Results: Patients with LC and PC before treatment showed a statistically significant increase in the level of circulating Treg cells compared with control values (p<0.05). Chemoradiotherapy with LC led to a significant decrease in the absolute number of Treg cells (p<0.05), but their relative number did not change significantly (p>0.05), which apparently indicates that this subpopulation of cells is not highly sensitive to treatment compared with other lymphocyte subsets. In contrast to Treg cells, the number of B and NK cells decreased more significantly, T helper cells decreased comparably, and T cytotoxic cells decreased to a lesser extent. PC brachytherapy had no statistically significant effect on the level of Treg cells and other lymphocyte subsets (p>0.05). The level of CD39 expression on Treg cells remained stable during treatment with LC and PC and corresponded to the control values (p>0.05).
Conclusion: The high content of Treg cells after chemoradiotherapy LC and PC brachytherapy indicates the persistence of immunosuppression at the systemic level, which negatively affects the results of treatment. The development of strategies for targeted modulation of Treg cells is necessary to increase the effectiveness of cancer therapy.
Keywords: regulatory T cells, lymphocyte subsets, lung cancer, chemoradiotherapy, prostate cancer, brachytherapy
For citation: Mushkarina TYu, Kuzmina EG, Grivtsova LYu, Afonin GV, Biryukov VA, Ivanov SA, Kaprin AD.Response of Circulating Regulatory T Cells to Chemoradiotherapy of Lung Cancer and Brachytherapy for Prostate Cancer. Medical Radiology and Radiation Safety. 2026;71(1):106–112. (In Russian). DOI:10.33266/1024-6177-2026-71-1-106-112
References
1. Ozerskaya Yu.V., Yusubaliyeva G.M., Zhukova O.A., Zykov K.A., Baklaushev V.P. Lung Cancer Immunotherapy: Status Quo, Problems, and Prospects. Meditsina Ekstremal’nykh Situatsiy = Medicine of Extreme Situations. 2024;26;4:87-97 (In Russ.). Doi: 10.47183/mes.2024-26-4-87-97.
2. Kireyeva T.A., Gumenetskaya Yu.V., Biryukov V.A., Obukhov A.A., Makarova K.S., Strikanova I.A., Dzhabrailova S.O. Prophylactic Irradiation of Pelvic Lymph Nodes in Patients with High-Risk Prostate Cancer Progression. Review. Radiatsiya i Risk (Byulleten’ Natsional’nogo Radiatsionnoepidemiologicheskogo Registra) = Radiation and Risk. 2021;30;4:94-107 (In Russ.). Doi: 10.21870/0131-3878-2021-30-4-94-107.
3. Kozlov V.A. Suppressor Cells – the Basis of Immunopathogenesis of Oncological Diseases. Voprosy Onkologii = Problems in Oncologyю 2016;62;3:390-396 (In Russ.).
4. Sennikov S.V., Khantakova Yu.N. The Role of T-Cell Subpopulations in the Induction of Immunological Tolerance. Immunologiya = Immunology. 2017;38;4:239-244 (In Russ.). Doi: 10.18821/0206-4952-2017-38-4-239-244.
5. Zhulay G.A., Oleynik Ye.K., Shibayev M.I., Semakova P.N., Oleynik V.M. Analysis of the Prognostic Significance of CD39 Ectonucleotide Expression by Peripheral Treg Cells in Patients with Colorectal Cancer. Vestnik Ural’skoy Meditsinskoy Akademicheskoy Nauki = Journal of Ural Medical Academic Science. 2020;17;4:323-332 (In Russ.). Doi: 10.22138/2500-0918-2020-17-4-323-332.
6. Vinod S.K., Hau E. Radiotherapy Treatment for Lung Cancer: Current Status and Future Directions. Respirology. 2020;25;2:61-71. Doi: 10.1111/resp.13870. PMID: 32516852.
7. Shchukina Ye.O., Biryukov V.A., Karyakin O.B., Ivanov S.A. High-Power Brachytherapy in Monomode in Patients with Localized Prostate Cancer. Eksperimental’naya i Klinicheskaya Urologiya = Experimental & Clinical Urology. 2023;16;3:136-145 (In Russ.). Doi: 10.29188/2222-8543-2023-16-3-136-145.
8. Qu Y., Jin S., Zhang A., Zhang B, Shi X., Wang J., Zhao Y. Gamma-Ray Resistance of Regulatory CD4+CD25+Foxp3+ T Cells in Mice. Radiat Res. 2010;173;2:148-57. Doi: 10.1667/RR0978.1. PMID: 20095846.
9. Liu R., Xiong S., Zhang L., Chu Y. Enhancement of Antitumor Immunity by Low-Dose Total Body Irradiationis Associated with Selectively Decreasing the Proportion and Number of T Regulatory Cells. Cell Mol Immunol. 2010;7;2:157-62. Doi: 10.1038/cmi.2009.117. PMID: 20140010.
10. Wang B., Li B., Dai Z., Ren S., Bai M., Wang Z., Li Z., Lin S., Wang Z., Huang N., Yang P., Liu M., Min W., Ma H. Low-Dose Splenic Radiation Inhibits Liver Tumor Development of Rats through Functional Changes in CD4+CD25+Treg Cells. Int J Biochem Cell Biol. 2014;55:98-108. Doi: 10.1016/j.biocel.2014. PMID: 25168696.
11. McKelvey K.J., Hudson A.L., Back M., Eade T., Diakos C.I. Radiation, Inflammation and the Immune Response in Cancer. Mamm Genome. 2018;29;11-12:843-865. Doi: 10.1007/s00335-018-9777-0. PMID: 30178305.
12. Principe D.R., Chiec L., Mohindra N.A., Munshi H.G. Regulatory T-Cells as an Emerging Barrier to Immune Checkpoint Inhibition in Lung Cancer. Front Oncol. 2021;11:684098. Doi: 10.3389/fonc.2021.684098. PMID: 34141625.
13. Popov S.V., Sturov N.V., Vorob’yev N.V., Khaydukov S.V. The Role of T-Regulatory Cells in the Progression of Prostate Cancer. Meditsinskaya Immunologiya = Medical Immunology (Russia). 2019;21;4:587-594 (In Russ.). Doi: 10.15789/1563-0625-2019-4-587-594.
14. Boustani J., Joseph E.L.M., Martin E., Benhmida S., Lecoester B., Tochet F., Mirjolet C., Chevalier C., Thibouw D., Vulquin N., Servagi S., Sun X., Adotévi O. Cisplatin-Based Chemoradiation Decreases Telomerase-Specific CD4 TH1 Response but Increases Immune Suppressive Cells in Peripheral Blood. BMC Immunol. 2021;22;1:38. Doi: 10.1186/s12865-021-00429-5. PMID: 34144673.
15. Dutsch-Wicherek M., Chaberek K., Makarewicz A., Antoni S.I., Witwicki J., Bielecki I., Wicherek Ł. The Analysis of Treg Lymphocyte Blood Percentage Changes in Patients with Head and Neck Cancer during Combined Oncological Treatment: a Preliminary Report. Cent Eur J Immunol. 2020;45;4:409-413. Doi: 10.5114/ceji.2020.103417. PMID: 33658889.
16. Baba J., Watanabe S., Saida Y., Tanaka T., Miyabayashi T., Koshio J., Ichikawa K., Nozaki K., Koya T., Deguchi K., Tan C., Miura S., Tanaka H., Tanaka J., Kagamu H., Yoshizawa H., Nakata K., Narita I. Depletion of Radio-Resistant Regulatory T Cells Enhances Antitumor Immunity during Recovery from Lymphopenia. Blood. 2012;120;12:2417-27. Doi: 10.1182/blood-2012-02-411124. PMID: 22806892.
17. Mougiakakos D., Johansson C.C., Kiessling R. Naturally Occurring Regulatory T Cells Show Reduced Sensitivity Toward Oxidative Stress-Induced Cell Death. Blood. 2009;113;15:3542-5. Doi: 10.1182/blood-2008-09-181040. PMID: 19050306.
18. Yarilin A.A. Immunologiya = Immunology. Textbook. Moscow, GEOTAR-Media Publ., 2010. 752 p. (In Russ.).
19. Schoenhals J.E., Cushman T.R., Barsoumian H.B., Li A., Cadena A.P., Niknam S., Younes A.I., Caetano M.D.S., Cortez M.A., Welsh J.W. Anti-Glucocorticoid-Induced Tumor Necrosis Factor-Related Protein (GITR) Therapy Overcomes Radiation-Induced Treg Immunosuppression and Drives Abscopal Effects. Front Immunol. 2018;9:2170. Doi: 10.3389/fimmu.2018.02170. PMID: 30294332.
PDF (RUS) Full-text article (in Russian)
Conflict of interest. The authors declare no conflict of interest.
Financing. The study had no sponsorship.
Contribution. T.Yu. Mushkarina – conducting research, performing statistical data analysis, drafting the manuscript; E.G. Kuzmina – scientific text editing, research design development, scientific guidance; L.Yu. Grivtsova – scientific text editing; G.V. Afonin – collecting research material; V.A. Biryukov – collecting the material; S.A. Ivanov – development of the research concept; A.D. Kaprin – development of the research concept.
Article received: 20.11.2025. Accepted for publication: 25.12.2025.